Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Mesoblast Limited ( (AU:MSB) ) is now available.
Mesoblast Limited announced the cessation of certain securities, specifically the expiration and lapse of options totaling 3,414,091 units, due to non-exercise and unmet conditions. This cessation reflects adjustments in the company’s issued capital, potentially impacting investor perceptions and future financial strategies.
More about Mesoblast Limited
Mesoblast Limited is a biotechnology company primarily focused on developing innovative cellular medicines. Their industry involves regenerative medicine and stem cell therapy, aimed at transforming patient outcomes in various medical fields.
YTD Price Performance: 140.91%
Average Trading Volume: 96,460
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.99B
For detailed information about MSB stock, go to TipRanks’ Stock Analysis page.
